Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

Abstract Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological and developmental characteristics of...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2025-08-01
Reeks:	BMC Gastroenterology
Onderwerpen:	Infliximab Adalimumab Adverse event Pharmacovigilance Pediatric Inflammatory bowel diseases
Online toegang:	https://doi.org/10.1186/s12876-025-04154-w
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!